ID   BMPR2_HUMAN             Reviewed;        1038 AA.
AC   Q13873; Q16569; Q4ZG08; Q53SA5; Q585T8;
DT   01-DEC-2000, integrated into UniProtKB/Swiss-Prot.
DT   01-DEC-2000, sequence version 2.
DT   05-OCT-2010, entry version 122.
DE   RecName: Full=Bone morphogenetic protein receptor type-2;
DE            Short=BMP type-2 receptor;
DE            Short=BMPR-2;
DE            EC=2.7.11.30;
DE   AltName: Full=Bone morphogenetic protein receptor type II;
DE            Short=BMP type II receptor;
DE            Short=BMPR-II;
DE   Flags: Precursor;
GN   Name=BMPR2; Synonyms=PPH1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Substantia nigra;
RX   MEDLINE=95372334; PubMed=7644468; DOI=10.1073/pnas.92.17.7632;
RA   Rosenzweig B.L., Imamura T., Okadome T., Cox G.N., Yamashita H.,
RA   ten Dijke P., Heldin C., Miyazono K.;
RT   "Cloning and characterization of a human type II receptor for bone
RT   morphogenetic proteins.";
RL   Proc. Natl. Acad. Sci. U.S.A. 92:7632-7636(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Skin fibroblast;
RX   MEDLINE=95403457; PubMed=7673243; DOI=10.1074/jbc.270.38.22522;
RA   Nohno T., Ishikawa T., Saito T., Hosokawa K., Noji S., Wosing D.H.,
RA   Rosenbaum J.S.;
RT   "Identification of a human type II receptor for bone morphogenetic
RT   protein-4 that forms differential heteromeric complexes with bone
RT   morphogenetic protein type I receptors.";
RL   J. Biol. Chem. 270:22522-22526(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   MEDLINE=95197572; PubMed=7890683; DOI=10.1074/jbc.270.10.5625;
RA   Kawabata M., Chytil A., Moses H.L.;
RT   "Cloning of a novel type II serine/threonine kinase receptor through
RT   interaction with the type I transforming growth factor-beta
RT   receptor.";
RL   J. Biol. Chem. 270:5625-5630(1995).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-586; SER-680; SER-681;
RP   SER-757 AND SER-863, AND MASS SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-375; THR-379; SER-513;
RP   SER-515; SER-680; SER-757 AND SER-862, AND MASS SPECTROMETRY.
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (2.35 ANGSTROMS) OF 189-517 IN COMPLEX WITH ADP.
RG   Structural genomics consortium (SGC);
RT   "Crystal structure of the BMPR2 kinase domain.";
RL   Submitted (FEB-2009) to the PDB data bank.
RN   [9]
RP   VARIANTS PPH1 GLN-491 AND TRP-491.
RX   MEDLINE=20395844; PubMed=10903931; DOI=10.1086/303059;
RA   Deng Z., Morse J.H., Slager S.L., Cuervo N., Moore K.J., Venetos G.,
RA   Kalachikov S., Cayanis E., Fischer S.G., Barst R.J., Hodge S.E.,
RA   Knowles J.A.;
RT   "Familial primary pulmonary hypertension (gene PPH1) is caused by
RT   mutations in the bone morphogenetic protein receptor-II gene.";
RL   Am. J. Hum. Genet. 67:737-744(2000).
RN   [10]
RP   VARIANTS PPH1 TYR-60; TYR-117 AND ARG-483.
RX   MEDLINE=20473811; PubMed=11015450; DOI=10.1136/jmg.37.10.741;
RA   Thomson J.R., Machado R.D., Pauciulo M.W., Morgan N.V., Humbert M.,
RA   Elliott G.C., Ward K., Yacoub M., Mikhail G., Rogers P., Newman J.H.,
RA   Wheeler L., Higenbottam T., Gibbs J.S.R., Egan J., Crozier A.,
RA   Peacock A., Allcock R., Corris P., Loyd J.E., Trembath R.C.,
RA   Nichols W.C.;
RT   "Sporadic primary pulmonary hypertension is associated with germline
RT   mutations of the gene encoding BMPR-II, a receptor member of the TGF-
RT   beta family.";
RL   J. Med. Genet. 37:741-745(2000).
RN   [11]
RP   VARIANTS PPH1 TRP-118; TYR-347 AND GLY-485.
RX   MEDLINE=20428187; PubMed=10973254; DOI=10.1038/79226;
RA   Lane K.B., Machado R.D., Pauciulo M.W., Thomson J.R.,
RA   Phillips J.A. III, Loyd J.E., Nichols W.C., Trembath R.C., Aldred M.,
RA   Brannon C.A., Conneally P.M., Foroud T., Fretwell N., Gaddipati R.,
RA   Koller D., Loyd E.J., Morgan N.V., Newman J.H., Prince M.A.,
RA   Vilarino Gueell C., Wheeler L.;
RT   "Heterozygous germline mutations in BMPR2, encoding a TGF-beta
RT   receptor, cause familial primary pulmonary hypertension.";
RL   Nat. Genet. 26:81-84(2000).
RN   [12]
RP   VARIANTS PPH1 ARG-123; SER-123; ARG-420 AND THR-512, VARIANT ASP-224,
RP   AND CHARACTERIZATION OF VARIANT PPH1 GLY-485.
RX   MEDLINE=21063176; PubMed=11115378; DOI=10.1086/316947;
RA   Machado R.D., Pauciulo M.W., Thomson J.R., Lane K.B., Morgan N.V.,
RA   Wheeler L., Phillips J.A. III, Newman J.H., Williams D., Galie N.,
RA   Manes A., McNeil K., Yacoub M., Mikhail G., Rogers P., Corris P.,
RA   Humbert M., Donnai D., Martensson G., Tranebjaerg L., Loyd J.E.,
RA   Trembath R.C., Nichols W.C.;
RT   "BMPR2 haploinsufficiency as the inherited molecular mechanism for
RT   primary pulmonary hypertension.";
RL   Am. J. Hum. Genet. 68:92-102(2001).
RN   [13]
RP   VARIANTS PPH1 HIS-82; ASP-182 AND ARG-483.
RX   PubMed=12358323; DOI=10.1183/09031936.02.01762002;
RA   Humbert M., Deng Z., Simonneau G., Barst R.J., Sitbon O., Wolf M.,
RA   Cuervo N., Moore K.J., Hodge S.E., Knowles J.A., Morse J.H.;
RT   "BMPR2 germline mutations in pulmonary hypertension associated with
RT   fenfluramine derivatives.";
RL   Eur. Respir. J. 20:518-523(2002).
RN   [14]
RP   INVOLVEMENT IN PVOD.
RX   PubMed=12446270;
RA   Runo J.R., Vnencak-Jones C.L., Prince M., Loyd J.E., Wheeler L.,
RA   Robbins I.M., Lane K.B., Newman J.H., Johnson J., Nichols W.C.,
RA   Phillips J.A. III;
RT   "Pulmonary veno-occlusive disease caused by an inherited mutation in
RT   bone morphogenetic protein receptor II.";
RL   Am. J. Respir. Crit. Care Med. 167:889-894(2003).
RN   [15]
RP   VARIANT PPH1 PRO-899, AND CHARACTERIZATION OF VARIANT PPH1 PRO-899.
RX   PubMed=15965979; DOI=10.1002/humu.20200;
RA   Sankelo M., Flanagan J.A., Machado R., Harrison R., Rudarakanchana N.,
RA   Morrell N., Dixon M., Halme M., Puolijoki H., Kere J., Elomaa O.,
RA   Kupari M., Raeisaenen-Sokolowski A., Trembath R.C., Laitinen T.;
RT   "BMPR2 mutations have short lifetime expectancy in primary pulmonary
RT   hypertension.";
RL   Hum. Mutat. 26:119-124(2005).
RN   [16]
RP   INVOLVEMENT IN PVOD.
RX   PubMed=16429395; DOI=10.1002/humu.20285;
RA   Machado R.D., Aldred M.A., James V., Harrison R.E., Patel B.,
RA   Schwalbe E.C., Gruenig E., Janssen B., Koehler R., Seeger W.,
RA   Eickelberg O., Olschewski H., Elliott C.G., Glissmeyer E.,
RA   Carlquist J., Kim M., Torbicki A., Fijalkowska A., Szewczyk G.,
RA   Parma J., Abramowicz M.J., Galie N., Morisaki H., Kyotani S.,
RA   Nakanishi N., Morisaki T., Humbert M., Simonneau G., Sitbon O.,
RA   Soubrier F., Coulet F., Morrell N.W., Trembath R.C.;
RT   "Mutations of the TGF-beta type II receptor BMPR2 in pulmonary
RT   arterial hypertension.";
RL   Hum. Mutat. 27:121-132(2006).
RN   [17]
RP   VARIANT [LARGE SCALE ANALYSIS] ASN-775.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: On ligand binding, forms a receptor complex consisting
CC       of two type II and two type I transmembrane serine/threonine
CC       kinases. Type II receptors phosphorylate and activate type I
CC       receptors which autophosphorylate, then bind and activate SMAD
CC       transcriptional regulators. Binds to BMP-7, BMP-2 and, less
CC       efficiently, BMP-4. Binding is weak but enhanced by the presence
CC       of type I receptors for BMPs.
CC   -!- CATALYTIC ACTIVITY: ATP + [receptor-protein] = ADP + [receptor-
CC       protein] phosphate.
CC   -!- COFACTOR: Magnesium or manganese (By similarity).
CC   -!- INTERACTION:
CC       Q91X48:C4bp (xeno); NbExp=1; IntAct=EBI-527196, EBI-527325;
CC       P68404:Prkcb (xeno); NbExp=2; IntAct=EBI-527196, EBI-397048;
CC   -!- SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane
CC       protein.
CC   -!- TISSUE SPECIFICITY: Highly expressed in heart and liver.
CC   -!- DISEASE: Defects in BMPR2 are the cause of primary pulmonary
CC       hypertension (PPH1) [MIM:178600]. PPH1 is a rare autosomal
CC       dominant disorder characterized by plexiform lesions of
CC       proliferating endothelial cells in pulmonary arterioles. The
CC       lesions lead to elevated pulmonary arterial pression, right
CC       ventricular failure, and death. The disease can occur from infancy
CC       throughout life and it has a mean age at onset of 36 years.
CC       Penetrance is reduced. Although familial PPH1 is rare, cases
CC       secondary to known etiologies are more common and include those
CC       associated with the appetite-suppressant drugs.
CC   -!- DISEASE: Defects in BMPR2 are a cause of pulmonary venoocclusive
CC       disease (PVOD) [MIM:265450]. PVOD is a rare form of pulmonary
CC       hypertension in which the vascular changes originate in the small
CC       pulmonary veins and venules. The pathogenesis is unknown and any
CC       link with PPH1 has been speculative. The finding of PVOD
CC       associated with a BMPR2 mutation reveals a possible pathogenetic
CC       connection with PPH1.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thr
CC       protein kinase family. TGFB receptor subfamily.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC   -!- WEB RESOURCE: Name=GeneReviews;
CC       URL="http://www.ncbi.nlm.nih.gov/sites/GeneTests/lab/gene/BMPR2";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; Z48923; CAA88759.1; -; mRNA.
DR   EMBL; D50516; BAA09094.1; -; mRNA.
DR   EMBL; U20165; AAC50105.1; -; mRNA.
DR   EMBL; AC009960; AAX76517.1; -; Genomic_DNA.
DR   EMBL; AC073410; AAX88941.1; -; Genomic_DNA.
DR   EMBL; AC064836; AAY24146.1; -; Genomic_DNA.
DR   EMBL; BC052985; AAH52985.1; -; mRNA.
DR   IPI; IPI00783156; -.
DR   PIR; I38935; I38935.
DR   RefSeq; NP_001195.2; -.
DR   UniGene; Hs.471119; -.
DR   PDB; 2HLQ; X-ray; 1.45 A; A=33-131.
DR   PDB; 3G2F; X-ray; 2.35 A; A/B=189-517.
DR   PDBsum; 2HLQ; -.
DR   PDBsum; 3G2F; -.
DR   ProteinModelPortal; Q13873; -.
DR   DIP; DIP-5794N; -.
DR   DIP; DIP-5941N; -.
DR   DIP; DIP-5942N; -.
DR   IntAct; Q13873; 38.
DR   STRING; Q13873; -.
DR   PhosphoSite; Q13873; -.
DR   PRIDE; Q13873; -.
DR   Ensembl; ENST00000374574; ENSP00000363702; ENSG00000204217.
DR   Ensembl; ENST00000374580; ENSP00000363708; ENSG00000204217.
DR   Ensembl; ENST00000445231; ENSP00000401728; ENSG00000204217.
DR   GeneID; 659; -.
DR   KEGG; hsa:659; -.
DR   UCSC; uc002uzf.2; human.
DR   CTD; 659; -.
DR   GeneCards; GC02P203205; -.
DR   H-InvDB; HIX0002749; -.
DR   HGNC; HGNC:1078; BMPR2.
DR   HPA; HPA017385; -.
DR   MIM; 178600; phenotype.
DR   MIM; 265450; phenotype.
DR   MIM; 600799; gene.
DR   Orphanet; 422; Idiopathic and/or familial pulmonary arterial hypertension.
DR   Orphanet; 31837; Pulmonary venoocclusive disease.
DR   PharmGKB; PA25388; -.
DR   HOGENOM; HBG447050; -.
DR   HOVERGEN; HBG050705; -.
DR   InParanoid; Q13873; -.
DR   OMA; GPTPVCL; -.
DR   OrthoDB; EOG90VZ90; -.
DR   BRENDA; 2.7.11.30; 247.
DR   Pathway_Interaction_DB; bmppathway; BMP receptor signaling.
DR   Reactome; REACT_12034; Signaling by BMP.
DR   NextBio; 2680; -.
DR   ArrayExpress; Q13873; -.
DR   Bgee; Q13873; -.
DR   CleanEx; HS_BMPR2; -.
DR   Genevestigator; Q13873; -.
DR   GermOnline; ENSG00000204217; Homo sapiens.
DR   GO; GO:0005887; C:integral to plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0005024; F:transforming growth factor beta receptor ac...; IEA:InterPro.
DR   GO; GO:0009952; P:anterior/posterior pattern formation; ISS:BHF-UCL.
DR   GO; GO:0030509; P:BMP signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0009267; P:cellular response to starvation; IEP:BHF-UCL.
DR   GO; GO:0048286; P:lung alveolus development; ISS:BHF-UCL.
DR   GO; GO:0001707; P:mesoderm formation; ISS:BHF-UCL.
DR   GO; GO:0030308; P:negative regulation of cell growth; IDA:UniProtKB.
DR   GO; GO:0003085; P:negative regulation of systemic arterial bl...; IMP:BHF-UCL.
DR   GO; GO:0045906; P:negative regulation of vasoconstriction; ISS:BHF-UCL.
DR   GO; GO:0030513; P:positive regulation of BMP signaling pathway; IMP:UniProtKB.
DR   GO; GO:0030501; P:positive regulation of bone mineralization; IMP:BHF-UCL.
DR   GO; GO:0010595; P:positive regulation of endothelial cell mig...; IMP:UniProtKB.
DR   GO; GO:0001938; P:positive regulation of endothelial cell pro...; IMP:UniProtKB.
DR   GO; GO:0010634; P:positive regulation of epithelial cell migr...; IDA:UniProtKB.
DR   GO; GO:0045669; P:positive regulation of osteoblast different...; IMP:BHF-UCL.
DR   GO; GO:0010862; P:positive regulation of pathway-restricted S...; IMP:UniProtKB.
DR   GO; GO:0014916; P:regulation of lung blood pressure; IMP:BHF-UCL.
DR   GO; GO:0006366; P:transcription from RNA polymerase II promoter; IMP:BHF-UCL.
DR   GO; GO:0048010; P:vascular endothelial growth factor receptor...; ISS:BHF-UCL.
DR   InterPro; IPR000472; Activin_rcpt.
DR   InterPro; IPR015770; BMPRII.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_cat_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR017442; Se/Thr_prot_kinase-like_dom.
DR   PANTHER; PTHR23255:SF12; BMPRII; 1.
DR   Pfam; PF01064; Activin_recp; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   SUPFAM; SSF56112; Kinase_like; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; FALSE_NEG.
PE   1: Evidence at protein level;
KW   3D-structure; ATP-binding; Complete proteome; Disease mutation;
KW   Disulfide bond; Glycoprotein; Kinase; Magnesium; Manganese; Membrane;
KW   Metal-binding; Nucleotide-binding; Phosphoprotein; Polymorphism;
KW   Receptor; Serine/threonine-protein kinase; Signal; Transferase;
KW   Transmembrane; Transmembrane helix.
FT   SIGNAL        1     26       Potential.
FT   CHAIN        27   1038       Bone morphogenetic protein receptor type-
FT                                2.
FT                                /FTId=PRO_0000024415.
FT   TOPO_DOM     27    150       Extracellular (Potential).
FT   TRANSMEM    151    171       Helical; (Potential).
FT   TOPO_DOM    172   1038       Cytoplasmic (Potential).
FT   DOMAIN      203    504       Protein kinase.
FT   NP_BIND     209    217       ATP.
FT   NP_BIND     280    282       ATP.
FT   NP_BIND     337    338       ATP.
FT   COMPBIAS    547    550       Poly-Ser.
FT   COMPBIAS    610    618       Poly-Thr.
FT   COMPBIAS    901    908       Poly-Asn.
FT   ACT_SITE    333    333       Proton acceptor (By similarity).
FT   BINDING     230    230       ATP.
FT   BINDING     351    351       ATP.
FT   MOD_RES     375    375       Phosphoserine.
FT   MOD_RES     379    379       Phosphothreonine.
FT   MOD_RES     513    513       Phosphoserine.
FT   MOD_RES     515    515       Phosphoserine.
FT   MOD_RES     586    586       Phosphoserine.
FT   MOD_RES     680    680       Phosphoserine.
FT   MOD_RES     681    681       Phosphoserine.
FT   MOD_RES     757    757       Phosphoserine.
FT   MOD_RES     862    862       Phosphoserine.
FT   MOD_RES     863    863       Phosphoserine.
FT   CARBOHYD     55     55       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    110    110       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    126    126       N-linked (GlcNAc...) (Potential).
FT   DISULFID     34     66       By similarity.
FT   DISULFID     94    117       By similarity.
FT   VARIANT      60     60       C -> Y (in PPH1).
FT                                /FTId=VAR_013670.
FT   VARIANT      82     82       Q -> H (in PPH1).
FT                                /FTId=VAR_033109.
FT   VARIANT     117    117       C -> Y (in PPH1).
FT                                /FTId=VAR_013671.
FT   VARIANT     118    118       C -> W (in PPH1).
FT                                /FTId=VAR_013672.
FT   VARIANT     123    123       C -> R (in PPH1).
FT                                /FTId=VAR_013673.
FT   VARIANT     123    123       C -> S (in PPH1).
FT                                /FTId=VAR_013674.
FT   VARIANT     182    182       G -> D (in PPH1).
FT                                /FTId=VAR_033110.
FT   VARIANT     224    224       E -> D.
FT                                /FTId=VAR_013675.
FT   VARIANT     347    347       C -> Y (in PPH1).
FT                                /FTId=VAR_013676.
FT   VARIANT     420    420       C -> R (in PPH1).
FT                                /FTId=VAR_013677.
FT   VARIANT     483    483       C -> R (in PPH1; sporadic).
FT                                /FTId=VAR_013678.
FT   VARIANT     485    485       D -> G (in PPH1; complete loss of
FT                                function).
FT                                /FTId=VAR_013679.
FT   VARIANT     491    491       R -> Q (in PPH1; sporadic).
FT                                /FTId=VAR_013680.
FT   VARIANT     491    491       R -> W (in PPH1).
FT                                /FTId=VAR_013681.
FT   VARIANT     512    512       K -> T (in PPH1).
FT                                /FTId=VAR_013682.
FT   VARIANT     519    519       N -> K (in PPH1).
FT                                /FTId=VAR_013683.
FT   VARIANT     775    775       S -> N (in dbSNP:rs2228545).
FT                                /FTId=VAR_019996.
FT   VARIANT     899    899       R -> P (in PPH1; leads to constitutive
FT                                activation of the MAPK14 pathway).
FT                                /FTId=VAR_033111.
FT   CONFLICT    828    828       G -> R (in Ref. 1; CAA88759).
FT   STRAND      228    233
FT   HELIX       234    236
FT   HELIX       237    247
FT   STRAND      260    262
FT   STRAND      264    267
FT   STRAND      273    279
FT   HELIX       287    293
FT   HELIX       298    309
FT   HELIX       313    316
FT   STRAND      338    341
FT   STRAND      347    349
FT   HELIX       380    382
FT   HELIX       385    388
FT   HELIX       394    396
FT   HELIX       397    408
FT   HELIX       412    417
FT   HELIX       421    423
FT   TURN        435    439
FT   HELIX       446    453
FT   HELIX       471    483
FT   HELIX       488    490
FT   HELIX       494    506
SQ   SEQUENCE   1038 AA;  115201 MW;  1389923CE574B913 CRC64;
     MTSSLQRPWR VPWLPWTILL VSTAAASQNQ ERLCAFKDPY QQDLGIGESR ISHENGTILC
     SKGSTCYGLW EKSKGDINLV KQGCWSHIGD PQECHYEECV VTTTPPSIQN GTYRFCCCST
     DLCNVNFTEN FPPPDTTPLS PPHSFNRDET IIIALASVSV LAVLIVALCF GYRMLTGDRK
     QGLHSMNMME AAASEPSLDL DNLKLLELIG RGRYGAVYKG SLDERPVAVK VFSFANRQNF
     INEKNIYRVP LMEHDNIARF IVGDERVTAD GRMEYLLVME YYPNGSLCKY LSLHTSDWVS
     SCRLAHSVTR GLAYLHTELP RGDHYKPAIS HRDLNSRNVL VKNDGTCVIS DFGLSMRLTG
     NRLVRPGEED NAAISEVGTI RYMAPEVLEG AVNLRDCESA LKQVDMYALG LIYWEIFMRC
     TDLFPGESVP EYQMAFQTEV GNHPTFEDMQ VLVSREKQRP KFPEAWKENS LAVRSLKETI
     EDCWDQDAEA RLTAQCAEER MAELMMIWER NKSVSPTVNP MSTAMQNERN LSHNRRVPKI
     GPYPDYSSSS YIEDSIHHTD SIVKNISSEH SMSSTPLTIG EKNRNSINYE RQQAQARIPS
     PETSVTSLST NTTTTNTTGL TPSTGMTTIS EMPYPDETNL HTTNVAQSIG PTPVCLQLTE
     EDLETNKLDP KEVDKNLKES SDENLMEHSL KQFSGPDPLS STSSSLLYPL IKLAVEATGQ
     QDFTQTANGQ ACLIPDVLPT QIYPLPKQQN LPKRPTSLPL NTKNSTKEPR LKFGSKHKSN
     LKQVETGVAK MNTINAAEPH VVTVTMNGVA GRNHSVNSHA ATTQYANGTV LSGQTTNIVT
     HRAQEMLQNQ FIGEDTRLNI NSSPDEHEPL LRREQQAGHD EGVLDRLVDR RERPLEGGRT
     NSNNNNSNPC SEQDVLAQGV PSTAADPGPS KPRRAQRPNS LDLSATNVLD GSSIQIGEST
     QDGKSGSGEK IKKRVKTPYS LKRWRPSTWV ISTESLDCEV NNNGSNRAVH SKSSTAVYLA
     EGGTATTMVS KDIGMNCL
//
